Literature DB >> 29974837

The role of benzathine penicillin G in predicting and preventing all-cause acute respiratory disease in military recruits: 1991-2017.

Jacob D Ball1, Mattia A Prosperi1, Alfonza Brown2, Xinguang Chen1, Eben Kenah3, Yang Yang4, Derek A T Cummings4, Caitlin M Rivers2.   

Abstract

The adenovirus vaccine and benzathine penicillin G (BPG) have been used by the US military to prevent acute respiratory diseases (ARD) in trainees, though these interventions have had documented manufacturing problems. We fit Poisson regression and random forest models (RF) to 26 years of weekly ARD incidence data to explore the impact of the adenovirus vaccine and BPG prophylaxis on respiratory disease burden. Adenovirus vaccine availability was among the most important predictors of ARD in the RF, while BPG was the ninth most important. BPG was a significant protective factor against ARD (incidence rate ratio (IRR) = 0.68; 95% confidence interval (CI) 0.67-0.70), but less so than either the old or new adenovirus vaccine (IRR = 0.39, 95% CI 0.38-0.39 and IRR = 0.11, 95% CI 0.11-0.11), respectively. These results suggest that BPG is moderately predictive of, and significantly protective against ARD, though to a lesser extent than either the old or new adenovirus vaccine.

Entities:  

Keywords:  Adenovirus; military; predictive models; prophylaxis; respiratory disease

Mesh:

Substances:

Year:  2018        PMID: 29974837      PMCID: PMC9506690          DOI: 10.1017/S0950268818001838

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  19 in total

1.  Benzathine penicillin G: its effectiveness in the prevention of streptococcal infections in a heavily exposed population.

Authors:  J DAVIS; W C SCHMIDT
Journal:  N Engl J Med       Date:  1957-02-21       Impact factor: 91.245

Review 2.  Immune function in sport and exercise.

Authors:  Michael Gleeson
Journal:  J Appl Physiol (1985)       Date:  2007-02-15

3.  Random forests for classification in ecology.

Authors:  D Richard Cutler; Thomas C Edwards; Karen H Beard; Adele Cutler; Kyle T Hess; Jacob Gibson; Joshua J Lawler
Journal:  Ecology       Date:  2007-11       Impact factor: 5.499

4.  Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines.

Authors:  Jennifer M Radin; Anthony W Hawksworth; Patrick J Blair; Dennis J Faix; Rema Raman; Kevin L Russell; Gregory C Gray
Journal:  Clin Infect Dis       Date:  2014-07-02       Impact factor: 9.079

5.  Broad and persistent effects of benzathine penicillin G in the prevention of febrile, acute respiratory disease.

Authors:  J D Gunzenhauser; J F Brundage; J G McNeil; R N Miller
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

6.  Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease.

Authors:  G C Gray; D C McPhate; M Leinonen; G H Cassell; E P Deperalta; S D Putnam; J A Karcher; M H Sawyer; A Laurila; J D Connor
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

Review 7.  Respiratory Infections in the U.S. Military: Recent Experience and Control.

Authors:  Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 8.  Respiratory diseases among U.S. military personnel: countering emerging threats.

Authors:  G C Gray; J D Callahan; A W Hawksworth; C A Fisher; J C Gaydos
Journal:  Emerg Infect Dis       Date:  1999 May-Jun       Impact factor: 6.883

9.  Respiratory disease in Army recruits: surveillance program overview, 1995-2006.

Authors:  Seung-Eun Lee; Angelia Eick; Paul Ciminera
Journal:  Am J Prev Med       Date:  2008-05       Impact factor: 5.043

10.  Serum penicillin G levels are lower than expected in adults within two weeks of administration of 1.2 million units.

Authors:  Michael P Broderick; Christian J Hansen; Kevin L Russell; Edward L Kaplan; Jeffrey L Blumer; Dennis J Faix
Journal:  PLoS One       Date:  2011-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.